Actively Recruiting
Open-Label Study Evaluating ALT001 Nerve Repair Protein Treatment for Multiple System Atrophy Patients in a Real-World Setting
Led by yilong Wang · Updated on 2026-09-09
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Multiple system atrophy MSA is a progressive neurodegenerative disorder that causes a combination of autonomic dysfunction, Parkinsons symptoms, and cerebellar problems. It has a low incidence but significantly impacts older adults, with most patients experiencing rapid decline in mobility and quality of life. Current treatments do not adequately address the disease progression, highlighting the need for new therapies that may protect or repair nerve tissue. This study evaluates ALT001, a nerve repair protein derived from stem cell exosomes, for its safety, tolerability, and preliminary effectiveness in treating MSA. Participants will receive three 30-day treatment cycles of ALT001 through daily intravenous infusions during the first 14 days of each cycle. The study expands previous research by including a broader group of MSA patients and is conducted in a real-world setting. Participants will undergo regular assessments including vital signs, laboratory tests, and neurological evaluations such as the Unified Multiple System Atrophy Rating Scale UMSARS and Composite Autonomic Symptom Score COMPASS. Evaluations occur at each treatment cycle and 180 days after treatment ends. Additional visits may happen if new neurological symptoms arise. The study monitors adverse events and changes in neurological function to understand ALT001s impact over time.
CONDITIONS
Brief Title
Expansion Study of ALT001 in Patients With Multiple System Atrophy
Research Team
W
Weiqi Chen
Y
Yahui Zhu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here